Results 171 to 180 of about 7,553 (206)

Mutations in Bruton’s tyrosine kinase impair IgA responses

International Journal of Hematology, 2015
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in Bruton's tyrosine kinase (BTK), and is characterized by markedly decreased numbers of blood B cells and an absence of all immunoglobulin isotypes. We performed whole exome sequencing in a male pediatric patient with dysgammaglobulinemia with IgA deficiency.
Mitsuiki, N, Yang, X, Bartol, Benjamin, Grosserichter - Wagener, Christina, Kosaka, Y, Takada, H, Imai, K, Kanegane, H, Mizutani, S, van der Burg, Mirjam, van Zelm, Menno, Ohara, O, Morio, T   +12 more
openaire   +2 more sources

Clinical Potential of Targeting Bruton's Tyrosine Kinase

International Reviews of Immunology, 2008
Targeting Bruton's tyrosine kinase (BTK) with a small-molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the antiapoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit antithrombotic properties, which may be desirable in the context of the increased risk of thromboembolic complications ...
openaire   +2 more sources

Brutons Tyrosine Kinase as a New Therapeutic Target

Anti-Cancer Agents in Medicinal Chemistry, 2007
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic ...
Fatih M, Uckun, Heather E, Tibbles, Alexei O, Vassilev   +2 more
openaire   +2 more sources

Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia

Seminars in Oncology, 2016
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and remains incurable outside of the setting of allogeneic stem cell transplant. While the standard therapy for both initial and relapsed CLL has traditionally included monoclonal antibody therapy in combination with chemotherapy, there are patients with high-risk disease features ...
Kami, Maddocks, Jeffrey A, Jones
openaire   +2 more sources

Genetic Variation in Bruton Tyrosine Kinase

2015
X-linked agammaglobulinemia (XLA) is a hereditary immunodeficiency caused by variations in the gene encoding for Bruton’s tyrosine kinase (BTK). Patients with XLA have decreased numbers of mature B cells, lack all immunoglobulin isotypes, and therefore have susceptibility to severe bacterial infections. XLA-causing variations are collected into BTKbase
Gerard C. P. Schaafsma, Mauno Vihinen
openaire   +1 more source

Next-Generation Bruton Tyrosine Kinase Inhibitors

Journal of Clinical Oncology, 2020
Deborah M, Stephens, John C, Byrd
openaire   +2 more sources

Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis

British Journal of Pharmacology
AbstractBackground and PurposePathological retinal angiogenesis is a typical manifestation of vision‐threatening ocular diseases. Many patients exhibit poor response or resistance to anti‐vascular endothelial growth factor (VEGF) agents. Bruton's tyrosine kinase (BTK) controls the proliferation and function of immune cells.
Siyue Chen, Yuming Liu, Yutian Zhang, Xu Guo, Tinghui Bai, Kai He, Yanfang Zhu, Yi Lei, Mei Du, Xiaohong Wang, Qiang Liu, Hua Yan   +11 more
openaire   +2 more sources

Bruton's tyrosine kinase in systemic lupus erythematosus

Joint Bone Spine, 2020
Hsien-Tzung Liao, Hsiang-Yuen Tung, Chang-Youh Tsai, Bor-Luen Chiang, Chia-Li Yu   +4 more
openaire   +2 more sources

Bruton's Tyrosine Kinase

2008
openaire   +1 more source

Bruton’s Tyrosine Kinase

2018
openaire   +1 more source